Investigation of tramadol pharmacokinetics and clinical responses in Japanese patients with head and neck cancer receiving oral tramadol

Investigation of tramadol pharmacokinetics and clinical responses in Japanese patients with head and neck cancer receiving oral tramadol - Investigation of tramadol pharmacokinetics and clinical responses in Japanese patients with head and neck cancer receiving oral tramadol

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039308

Enrollment

100

Registered

2020-01-30

Start date

2018-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer pain

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients receiving oral tramadol for pain 2. Patients receiving written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients discontinuing oral tramadol 2. Patients having severe kidney dysfunction or liver dysfunction 3. Patients who have a difficulty in determination of genotype using peripheral blood sample 4. Patients who are judged by physicians as inappropriate for study enrollment

Design outcomes

Primary

Measure	Time frame
Plasma concentrations of tramadol, O-desmethyltramadol, N-desmethyltramadol and N,O-didesmethyltramadol 96 hours and later starting oral tramadol.	—

Countries

Japan

Contacts

Public ContactTakafumi Naito

Hamamatsu University School of Medicine Department of Hospital pharmacy

pharmacyham-adm@umin.ac.jp053-435-2763

Outcome results